Novavax (NVAX) Return on Capital Employed (2011 - 2026)
Novavax (NVAX) posted quarterly Return on Capital Employed of 10.18% for Q1 2026, down 5114.0% year-over-year from 0.2% in Q1 2025, and down 116.15% quarter-over-quarter from 63.04% in Q4 2025.
Novavax (NVAX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Novavax's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 10.18% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5114.0% year-over-year to 10.18%; the TTM figure through Mar 2026 stood at 10.18% (down 5114.0% YoY), while the FY2025 annual figure was 49.84%, up 9730.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 10.18%, down from 63.04% in the prior quarter.
- The five-year high for Return on Capital Employed was 6421.91% in Q1 2023, with the low at 3566.59% in Q2 2023.
- The 5-year median for Return on Capital Employed is 51.64% (2024), against an average of 89.17%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 670712 bps in 2023, then plunged 647359 bps in 2024.
- Novavax's Return on Capital Employed stood at 327.47% in 2022, then plunged by 288 bps to 614.53% in 2023, then jumped by 92 bps to 51.64% in 2024, then jumped by 222 bps to 63.04% in 2025, then slumped by 116 bps to 10.18% in 2026.
- Business Quant data shows NVAX's Return on Capital Employed at 10.18% in Q1 2026, 63.04% in Q4 2025, and 37.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -35.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.01% |
| Mar 31, 2026 | -10.18% |
| Dec 31, 2025 | 63.04% |
| Sep 30, 2025 | 37.12% |
| Jun 30, 2025 | 37.97% |
| Mar 31, 2025 | 40.96% |
| Dec 31, 2024 | -51.64% |
| Sep 30, 2024 | -51.56% |
| Jun 30, 2024 | -68.42% |
| Mar 31, 2024 | -51.69% |
| Dec 31, 2023 | -614.53% |
| Sep 30, 2023 | -309.52% |
| Jun 30, 2023 | -3,566.59% |
| Mar 31, 2023 | 6,421.91% |
| Dec 31, 2022 | 327.47% |
| Sep 30, 2022 | -157.71% |
| Jun 30, 2022 | -245.47% |
| Mar 31, 2022 | -285.21% |
| Dec 31, 2021 | -931.67% |
| Sep 30, 2021 | -115.49% |